New Data From ASCO's TAPUR Study to be Presented at 2020 Gastrointestinal Cancers Symposium

For immediate release
January 24, 2020

Contact
Savannah Rogers
571-483-1592
savannah.rogers@asco.org

SAN FRANCISCO- Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California.

The TAPUR Study is the first clinical trial conducted by ASCO and aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Read more about how the TAPUR Study illustrates the power of personalized treatment in colorectal cancer in ASCO Daily News or contact the Media Team to speak with an expert in gastrointestinal cancers about the studies below.

Abstract 122:
Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.

Poster Session C: Anal and Colorectal Cancer
Saturday, January 25, 2020: 6:30 AM - 7:55 AM PT
Hirva Mamdani, MD
Indiana University
Bloomington, Indiana

Saturday, January 25, 2020: 12:15 PM - 1:45 PM PT
The Moscone West Building, Level 1, West Hall
Abstract 132:

**Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.**

Ranju Gupta, MD  
Lehigh Valley Health Network  
Bethlehem, PA

Poster Session C: Anal and Colorectal Cancer  
Saturday, January 25, 2020: 6:30 AM - 7:55 AM PT  
Saturday, January 25, 2020: 12:15 PM - 1:45 PM PT  
The Moscone West Building, Level 1, West Hall

Abstract 133:

**Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.**

Eyal Meiri, MD  
Cancer Treatment Centers of America  
Atlanta, GA

Poster Session C: Anal and Colorectal Cancer  
Saturday, January 25, 2020: 6:30 AM - 7:55 AM PT  
Saturday, January 25, 2020: 12:15 PM - 1:45 PM PT  
The Moscone West Building, Level 1, West Hall

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube.